Use of follistatin-like 1 (fstl1) in cardiometabolic heart failure
AssigneeRegencor, Inc.
InventorsThomas B. OKARMA, Pilar RUIZ-LOZANO
Life of this patent
Estimating the term…
Abstract
Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors, such as follistatin-like 1 (FSTL1), for aiding treatment of cardiometabolic heart failures, as well as methods for using the same.
Claims37
A method of aiding cardiometabolic heart failure treatment, the method comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.
A method of treating cardiometabolic heart failure, the method comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.
A method of repairing cardiac tissue following cardiometabolic heart failure, the method comprising contacting the cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.
Dependencies are inferred from the claim text.